Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, Kazem Nasserinejad, Thomas Pabst, Johan A. Maertens, Dimitri A. Breems, Markus G Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Lowenberg, Gerwin A. Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen, Jurjen Versluis

Blood (2022) 140 (Supplement 1): 127–129.

https://doi.org/10.1182/blood-2022-158137

Published: 2022

Journal Articles

CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK

Priyanka Mehta, Anjum Khan, Jamie Maddox, Yngvar Floisand, Richard Whitmill, Daniel Cuadras, Montse Pedros, Saemi Park, Greg Medalla, Alex Legg, Victoria Louise Campbell

Blood (2022) 140 (Supplement 1): 6152–6154.

https://doi.org/10.1182/blood-2022-159496

Published: 2022

Journal Articles

A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML

Yngvar Floisand, MD PhD, Iris Bigalke, MD, Dag Josefsen, MD PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Richard Addo, MD PhD, Dolores J. Schendel, PhD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-139255

Published: 2020

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study

Sunu Cyriac, MD MBBS, Auro Viswabandya, MD, Zeyad Al-Shaibani, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Wilson Lam, MD, Dennis Dong Hwan Kim, MD, Arjun Law, MDDM, Tobias Gedde-Dahl, MD PhD, Yngvar Floisand, MD PhD, Mats Remberger, PhD, Jonas Mattsson, MD, Fotios V. Michelis, MD PhD

Blood (2019) 134 (Supplement_1): 3341.

https://doi.org/10.1182/blood-2019-125941

Published: 2019

Journal Articles

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Judith Eckl, PhD, Silke Raffegerst, PhD, Frauke Schnorfeil, PhD, Petra Prinz-Schulz, PhD, Christiane Fingerhut, Yngvar Floisand, MD PhD, Dag Josefsen, Iris Bigalke, MD, Kai Pinkernell, MDMBA, Gunnar Kvalheim, MD PhD, Dolores Schendel, Prof., Anna Tafuri, MD

Blood (2019) 134 (Supplement_1): 3923.

https://doi.org/10.1182/blood-2019-129749

Published: 2019

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

Journal Articles

A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy

Benedicte Sjo Tislevoll, MD, Oda Helen Eck Fagerholt, Nello Blaser, MS, PhD, Monica Hellesøy, MS, PhD, Stein-Erik Gullaksen, MS, PhD, Pilar Ayuda Duran, MS, PhD, Laure Isabelle Piechaczyk, MS, Dagim Tadele, MS, Jørn Skavland, MS, PhD, Sonia Gavasso, MS, PhD, Jorrit Enserink, MS, PhD, Yngvar Fløisand, MD PhD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2018-99-116943

Published: 2018

Journal Articles

Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Iris Bigalke, MD, Judith Eckl, PhD, Guri Solum, MSc, Kirsti Hønnåshagen, Msc, Lisbeth Skoge, MSc, Yngvar Fløisand, MD PhD, Dag Josefsen, MD PhD, Stein Sæbøe-Larssen, PhD, Christiane Geiger, PhD, Dolores Schendel, PhD, Gunnar Kvalheim, MD PhD

Blood (2018) 132 (Supplement 1): 2718.

https://doi.org/10.1182/blood-2018-99-114557

Published: 2018

Journal Articles

Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support

Dag Josefsen, MD PhD, Yngvar Fløisand, MD PhD, Harald Holte, Jr., MD PhD, Gunnar Kvalheim, MD PhD

Blood (2016) 128 (22): 5826.

https://doi.org/10.1182/blood.V128.22.5826.5826

Published: 2016

Journal Articles

AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome

Iris Bigalke, Yngvar Fløisand, MD PhD, Guri Solum, Kirsti Hønnåshagen, Marianne Lundby, Kristina Anderson, MD PhD, Stein Sæbøe-Larssen, PhD, Else-Marit Inderberg, PhD, Judith Eckl, PhD, Dolores J Schendel, PhD, Gunnar Kvalheim, MD PhD

Blood (2015) 126 (23): 3798.

https://doi.org/10.1182/blood.V126.23.3798.3798

Published: 2015

Journal Articles

Acute Myeloid Leukaemia Treatment in Adults in Norway Five Year Survival and Costs

Alette Glasø Skifjeld, Beate Bjørnstad, Yngvar Fløisand, MD PhD, Eline Aas, PhD

Blood (2015) 126 (23): 4490.

https://doi.org/10.1182/blood.V126.23.4490.4490

Published: 2015

Journal Articles

Targeting Integrin a4b7-Expressing T-Cells in Steroid Refractory Intestinal GvHD

Yngvar Floisand, MDPhD, Knut Lundin, MDPhD, Vladimir Lazarevic, MD, Jorn Dehli Kristiansen, RN, Liv T. N. Osnes, MD PhD, Geir E. Tjonnfjord, MD PhD, Henrik Mikael Reims, MDPhD, Tobias Gedde-Dahl, MDPhD

Blood (2015) 126 (23): 3137.

https://doi.org/10.1182/blood.V126.23.3137.3137

Published: 2015

Journal Articles

The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpcs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival

Dag Josefsen, MD, PhD, Geir Hetland, MD, PhD, Yngvar Fløisand, MD, Ph.D, Harald Holte, MD, PhD, Gunnar Kvalheim, MD, PhD

Blood (2013) 122 (21): 5517.

https://doi.org/10.1182/blood.V122.21.5517.5517

Published: 2013

Journal Articles

Plasmacytoid DCs regulate recall responses by rapid induction of IL-10 in memory T cells

Espen O. Kvale, Yngvar Fløisand, Fridtjof Lund-Johansen, Halvor Rollag, Lorant Farkas, Smita Ghanekar, Per Brandtzaeg, Frode L. Jahnsen, Johanna Olweus

Blood (2006) 109 (8): 3369–3376.

https://doi.org/10.1182/blood-2006-06-031484

Published: 2006

NARROW

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK

A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study

DC Vaccination Induces Antigen Specific Immune Responses in AML Patients: A 1-Year Interim Assessment

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy

Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use

Poor Mobilizing Lymphoma Patients Rescued By Addition of Plerixafor during Stem Cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose Therapy with Autologous Stem Cell Support

AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome

Acute Myeloid Leukaemia Treatment in Adults in Norway Five Year Survival and Costs

Targeting Integrin a4b7-Expressing T-Cells in Steroid Refractory Intestinal GvHD

The Use Of Plerixafor In Hard-To-Mobilize Lymphoma and Multiple Myeloma Patients Not Only Provide Sufficient Numbers Of Pbpcs To Proceed To High Dose Therapy, But Also Have a Positive Impact On Survival

Plasmacytoid DCs regulate recall responses by rapid induction of IL-10 in memory T cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only